Эффективность терапии карбоцистеином при обострении хронической обструктивной болезни легких
Abstract
Summary. This study was designed to evaluate clinical efficacy and safety of carbocysteine lysine salt in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). This was a prospective randomized comparative controlled trial involving 50 hospitalized patients with acute exacerbation of COPD. The patients were divided in 2 groups: the 1st group patients (n = 25) were treated with syrop of carbocysteine lysine salt (Fluifort) 4 050 mg daily during 10 days, the 2nd control group patients (n = 25) did not receive any mucoactive drugs. Clinical and spirometric parameters and C-reactive protein (CRP) level were serially assessed. At the 5th and 10th days of the treatment, clinical symptoms (cough intensity and sputum expectoration) differed significantly between groups in favor of the carbocysteine group (p < 0.05). FEV1 and FVC improved in both the groups at the 10th day of therapy. Other lung function parameters and peripheral blood leukocyte number did not differ significantly between the groups to the 10th day. CRP decreased significantly to the 10th day in the carbocysteine group compared to the controls (6.8 ± 2.3 vs 9.5 ± 1.2 mg × L–1; p < 0.05). Carbocysteine was well-tolerated by all the patients, serious adverse events were not registered. Therefore, addition of carbocysteine lysine salt (Fluifort), a mucoactive drug with antioxidant and anti-inflammatory properties, to a standard therapy of acute exacerbation of COPD has led to improvement of…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 50 participants or records.
Read the paper
Related studies
- Diagnosis and management of glutaric aciduria type I – revised recommendations
- EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas
- Consensus guidelines for the diagnosis and management of pyridoxine‐dependent epilepsy due to α‐aminoadipic semialdehyde dehydrogenase deficiency
- Systemic Metabolomic Changes in Blood Samples of Lung Cancer Patients Identified by Gas Chromatography Time-of-Flight Mass Spectrometry
- Human OTULIN haploinsufficiency impairs cell-intrinsic immunity to staphylococcal α-toxin
- Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.